Related Experiment Videos
[Management of prolactinomas during pregnancy]
Weilin Chen1, Xuming Bian, Mingying Gai
1Department of Obsterics and Gynecology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences Beijing 100730 China.
Objective:
To evaluate the safety of discontinuing drugs for prolactinoma during pregnancy, and the effect of prolactinoma on pregnancy.
Methods:
Thirty-two cases of prolactinoma in pregnancy were enrolled, 22 microadenoma and 10 macroadenoma.
Results:
Adenoma growing appeared in 6 cases. Among them 5 were macroadenoma, dopamine agonists were then reused and surgery were carried out in 2 of them. The other was one microadenoma, dopamine agonists was reinstituted. No side effect on fetus's weight and appearance was seen. Gestation complication was as normal.
Conclusions:
Discontinuing dopamine agonists is safe during pregnancy for microadenoma. The risk of macroadenoma enlargement during pregnancy is high. Regular visal field testing is necessary during pregnancy. Prolactinoma doesn't influence gestation complication and fetus.